Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 11 September 2025, the valuation grade for Hims & Hers Health, Inc. has moved from fair to expensive, indicating that the company is overvalued. Key ratios reflect this assessment, with a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10, all suggesting high valuation multiples relative to earnings and assets.
In comparison to peers, Hims & Hers Health, Inc. has a higher P/E ratio than Guardant Health, Inc. at -17.69 and RadNet, Inc. at 123.79, which also indicates a premium valuation. The company's PEG ratio of 0.01 further emphasizes its expensive standing in the market. Notably, Hims & Hers has significantly outperformed the S&P 500 over various periods, with a year-to-date return of 132.42% compared to the S&P 500's 12.22%, reinforcing the notion of a high valuation amidst strong performance.